Regulatory approval
Published by the Health Service Executive. Approved
The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and docetaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
This is written in the approval document as:
Pertuzumab is indicated in combination with trastuzumab and DOCEtaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease.
Reimbursement
Incomplete Reimbursement
Pertuzumab - ODMS; Docetaxel, Trastuzumab - N/A
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | HER2-positive | Invasive Breast Carcinoma | Docetaxel, Pertuzumab, Trastuzumab |
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2014-02-01 | Health Service Executive | Indication approved for reimbursement. |